Sarepta Therapeutics Reports Q3 Revenue Beat Amid Non-GAAP EPS Miss
Sarepta Therapeutics (SRPT) reported third-quarter financial results characterized by a significant earnings miss alongside a revenue beat. The company's non-GAAP earnings per share (EPS) came in at $0.13, falling short of expectations by $0.23. Despite the earnings shortfall, total revenue reached $381.3 million, exceeding analyst estimates by $31.2 million, even though this represents a 4.5% decline year-over-year. Operating costs also saw an increase, with selling, general and administrative (SG&A) expenses rising to $118.6 million from $91.9 million in the prior-year period.
Tickers: $SRPT